CUSMA agreement on IP protection puts Canadian innovation at risk

4 January 2020

The revised Intellectual Property Provisions negotiated as part of the Canada US Mexico Agreement (CUSMA) will discourage investment in Canadian health research and hurt our country’s competitiveness, commented Innovative Medicines Canada president Pamela Fralick in a website posting by the trade group.

“This is disappointing news for Canada’s innovative pharmaceutical industry, which is already facing significant challenges launching new medicines and attracting new investment in Canada given the severe anticipated impact of the recent amendments to Patented Medicines Regulations,” stated Ms Fralick.

“A strengthened IP regime would have helped to boost Canada’s competitiveness in the life sciences sector by creating a climate that fosters innovation. Instead, companies in the Canadian innovative pharmaceutical sector will face even greater challenges competing for global research funding,” she noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK